Your browser is no longer supported. Please, upgrade your browser.
Settings
MDVN [NASD]
Medivation, Inc.
Index- P/E36.68 EPS (ttm)3.30 Insider Own1.40% Shs Outstand78.23M Perf Week6.93%
Market Cap9.47B Forward P/E28.04 EPS next Y4.32 Insider Trans-26.41% Shs Float76.34M Perf Month12.15%
Income276.50M PEG- EPS next Q0.36 Inst Own96.60% Short Float5.27% Perf Quarter5.42%
Sales710.50M P/S13.33 EPS this Y-1.80% Inst Trans1.47% Short Ratio3.97 Perf Half Y35.28%
Book/sh3.23 P/B37.48 EPS next Y32.99% ROA24.30% Target Price121.83 Perf Year68.34%
Cash/sh4.10 P/C29.49 EPS next 5Y- ROE83.40% 52W Range54.37 - 122.00 Perf YTD21.52%
Dividend- P/FCF187.15 EPS past 5Y11.70% ROI-7.90% 52W High-0.36% Beta0.57
Dividend %- Quick Ratio4.80 Sales past 5Y85.00% Gross Margin- 52W Low123.58% ATR4.08
Employees485 Current Ratio4.80 Sales Q/Q234.20% Oper. Margin39.70% RSI (14)72.19 Volatility3.90% 3.68%
OptionableYes Debt/Eq0.88 EPS Q/Q633.30% Profit Margin16.20% Rel Volume0.65 Prev Close121.05
ShortableYes LT Debt/Eq0.88 EarningsFeb 25 AMC Payout0.00% Avg Volume1.01M Price121.56
Recom1.80 SMA2012.83% SMA5014.90% SMA20029.91% Volume551,375 Change0.42%
Mar-02-15Reiterated Maxim Group Buy $118 → $126
Feb-26-15Reiterated Brean Capital Buy $118 → $125
Jan-29-15Reiterated Stifel Buy $112 → $128
Jan-23-15Initiated RBC Capital Mkts Sector Perform $100
Dec-15-14Reiterated UBS Buy $110 → $125
Sep-18-14Upgrade Canaccord Genuity Hold → Buy $60 → $132
Sep-12-14Reiterated Chardan Capital Markets Buy $100 → $122
Sep-11-14Reiterated Stifel Buy $89 → $112
Aug-08-14Reiterated UBS Buy $85 → $90
Aug-08-14Reiterated Stifel Buy $83 → $89
Aug-08-14Reiterated Brean Capital Buy $100 → $105
May-22-14Initiated Stifel Buy $81
Apr-16-14Initiated Canaccord Genuity Hold $60
Mar-17-14Reiterated Maxim Group Buy $92 → $112
Mar-03-14Reiterated UBS Buy $93 → $85
Feb-28-14Reiterated Maxim Group Buy $84 → $92
Feb-03-14Reiterated Chardan Capital Markets Buy $100
Feb-03-14Downgrade Needham Buy → Hold
Jan-29-14Reiterated Maxim Group Buy $75 → $84
Jan-29-14Reiterated Brean Capital Buy $72 → $100
Feb-27-15 07:08PM  10-K for Medivation, Inc. Company Spotlight
05:44PM  Four Hot Stocks You'll Want To Keep On Your Radar at Investor's Business Daily
09:31AM  Medivation (MDVN) Shares March Higher, Can It Continue? - Tale of the Tape Zacks
06:47AM  Can anything slow Medivation? optionMONSTER
Feb-26-15 03:45PM  Growth-stock breakouts mean opportunity for speculators at MarketWatch +5.18%
12:12PM  Nasdaq, S&P 500 Hang Tough; Avago, Akorn Big Earnings Winners at Investor's Business Daily
11:20AM  Amgen Reports Encouraging Late-Stage Data on AMG 416 - Analyst Blog Zacks
10:20AM  Medivation Beats on Q4 Earnings & Revenues; Xtandi Soars - Analyst Blog Zacks
09:56AM  Medivation Tops Q4 Views On Strong Xtandi Results at Investor's Business Daily
Feb-25-15 07:15PM  Medivation beats Street 4Q forecasts AP
04:30PM  Medivation Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:24PM  MEDIVATION, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:10PM  Medivation Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update Marketwired
02:59PM  Stocks Mixed; United Therapeutics Jumps To New High at Investor's Business Daily
07:07AM  Q4 2014 Medivation Inc Earnings Release - After Market Close CCBN
Feb-24-15 07:00PM  Medivation Announces Participation at Upcoming Investor Conference Marketwired
Feb-23-15 03:05PM  Stocks Show Small Losses; Merger Talk Lifts Discovery at Investor's Business Daily
01:18PM  Stocks Quietly Lower; Domino's, Medivation Break Out at Investor's Business Daily
11:17AM  Biotech on the rise; Analyst likes Gilead CNBC
Feb-13-15 04:20PM  MEDIVATION, INC. Files SEC form 8-K, Material Modification to Rights of Security Holders, Change in Directors or Prin EDGAR Online
Feb-11-15 04:10PM  Medivation Announces Fourth Quarter and Year-End 2014 Financial Results Teleconference on February 25, 2015 Marketwired
Feb-04-15 12:45PM  4 picks for shelter from the volatility CNBC
Feb-02-15 06:06AM  MEDIVATION, INC. Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
Jan-30-15 11:39AM  Valeant Agrees To Buy Dendreon's Provenge at Investor's Business Daily
Jan-26-15 05:22PM  Medivation CEO's Planned Sale Hits $10.8M in Stock at Barrons.com
Jan-23-15 04:20PM  Medivation and Astellas Report TERRAIN Data on Xtandi - Analyst Blog Zacks
06:19AM  Coverage initiated on Medivation by RBC Capital Mkts Briefing.com
Jan-22-15 07:00AM  Enzalutamide Phase 2 Terrain Trial Demonstrated Statistically Significant Increase in PFS as Compared to Bicalutamide in Metastatic Prostate Cancer Marketwired
Jan-20-15 11:20AM  J&J Earnings Beat But Sales, Guidance Miss at Investor's Business Daily
Jan-06-15 10:05AM  UPDATE: Barclays Capital Initiates Coverage On Medivation On Multiple Upside Drivers Benzinga
Dec-29-14 07:18AM  Bullish on biotech CNBC
07:16AM  Top three pharma predictions for 2015 CNBC
Dec-22-14 04:10PM  Medivation Exercises License Option for Pidilizumab Marketwired -5.08%
Dec-18-14 08:20AM  Meet This Years Top Health Care ETF ETF Trends
Dec-12-14 06:00PM  Data Presented From Phase 2 Study of Enzalutamide in Advanced Androgen-Receptor Positive, Triple-Negative Breast Cancer Marketwired
Dec-10-14 04:10PM  Phase 3 PREVAIL Trial Named Clinical Advance of the Year by SCRIP Marketwired
Dec-09-14 05:26PM  MEDIVATION, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; EDGAR Online
Dec-01-14 01:00AM  US Federal Reserve will hike rates in June: Pro CNBC
Nov-28-14 05:20PM  Newly Profitable Medivation Riding High On Drug Sales at Investor's Business Daily
Nov-25-14 04:10PM  Joseph Lobacki to Become Medivation's Chief Commercial Officer Marketwired
Nov-17-14 04:10PM  Medivation CEO David Hung Named National EY Entrepreneur Of The Year 2014 Overall Award Winner Marketwired
Nov-14-14 02:30PM  Street Talk: HOG, LULU, BMRN, MDVN & TRS CNBC
01:04PM  MEDIVATION, INC. Financials EDGAR Online Financials
Nov-10-14 10:38AM  Dendreon files bankruptcy protection CNBC
Nov-08-14 07:07PM  10-Q for Medivation, Inc. Company Spotlight
Nov-07-14 04:28PM  Another lackluster session for major equities Yahoo Finance Blogs +7.45%
03:30PM  Major Upgrades And Downgrades In Friday's Market Action Benzinga
12:53PM  Clarification: Earns-Medivation story AP
12:35PM  Midday movers: Allergan, Freshpet, Transocean & more at CNBC
11:15AM  Medivation Hits High After Q3 Earnings Beat at Investor's Business Daily
11:08AM  Medivation Q3 Earnings, Revenues Lag Estimates Zacks
Nov-06-14 04:18PM  MEDIVATION, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:10PM  Medivation Reports Third Quarter Financial Results and Provides Corporate Update Marketwired
08:30AM  Deutsche Banks U.S. Stock Selection Best Buy Ideas at 24/7 Wall St.
07:07AM  Q3 2014 Medivation Inc Earnings Release - After Market Close CCBN
Nov-05-14 04:10PM  Medivation Announces Participation at Upcoming Investor Conference Marketwired
12:54PM  3 Biotech Stocks for Earnings Beats this Season Zacks
08:00AM  Strong Prostate Cancer Drug Sales Will Help Medivation Expand Pipeline at TheStreet
Nov-04-14 02:50PM  Will Humana (HUM) Miss on Earnings Estimates this Season? Zacks
05:32AM  Geron Corporation (GERN) Looks Strong: Stock Up 25.6% Zacks
Nov-03-14 11:50AM  Seattle Genetics Gains on Narrower-than-Expected Q3 Loss Zacks
05:28AM  Oncolytics Biotech (ONCY) Looks Strong: Stock Up 21.9% Zacks
02:23AM  Prosensa Holding N.V. (RNA) Jumps: Stock Moves Up 9.9% Zacks
Oct-31-14 03:11AM  Bristol-Myers Squibb (BMY) Jumps: Stock Moves Up 8.9% Zacks
03:07AM  Novo Nordisk A/S (NVO) Shows Strength: Stock Up 6.2% Zacks
Oct-30-14 11:00PM  Medivation and Astellas Announce Phase 3 Study of Enzalutamide in Men With High-Risk, Hormone-Sensitive, Non-Metastatic Prostate Cancer That Has Recurred Following Definitive Local Therapy Marketwired
Oct-28-14 04:10PM  Medivation Announces Participation at Upcoming Investor Conference Marketwired
06:27AM  Novavax (NVAX) in Focus: Stock Rises 13% Zacks
Oct-27-14 02:15AM  Verastem (VSTM) Shows Strength: Stock Adds 7% in Session Zacks
Oct-24-14 04:25PM  Biogen Falls on Concerns Regarding Tecfidera Sales and PML Case Zacks
01:00PM  BioMarin Q3 Loss Narrower than Expected, View Raised Zacks
08:55AM  Eli Lilly's Q3 Earnings In-Line but Generics Hit Revenues Zacks
06:47AM  Fate Therapeutics (FATE) Crumbles: Stock Tumbles by 10.6% Zacks
Oct-23-14 05:12PM  Medivation Inc. Licenses Clinical Stage Anti-PD-1 Immune Modulatory Monoclonal Antibody From CureTech Ltd. for Potential Applications in Oncology Marketwired
04:00PM  Medivation Announces Third Quarter 2014 Financial Results Teleconference on November 6, 2014 Marketwired
03:10PM  Omeros Falls as Enrollment for OMS824 Study is Suspended Zacks
02:30PM  Novartis' Secukinumab Receives Favorable FDA Panel Vote Zacks
11:50AM  Celgene Beats Q3 Earnings Estimates on High Revlimid Sales Zacks
Oct-22-14 12:14PM  Value in biotech: Pro CNBC
07:32AM  Orexigen (OREX) Shows Strength: Stock Gains 11.1% Zacks
06:43AM  Illumina (ILMN) Looks Strong: Stock Gains 9.2% Zacks
Oct-21-14 05:05PM  NewLink-Roche Ink Deal for Oncology Candidate Development Zacks
02:30PM  Will Quest Diagnostics (DGX) Surprise Earnings in Q3? Zacks
Oct-17-14 05:07PM  MEDIVATION, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
04:00PM  Infinity Pharmaceuticals' Duvelisib Fails in Mid-Stage Study Zacks
03:30PM  Gilead's Harvoni Receives Notice of Compliance from Canada Zacks
Oct-15-14 05:48PM  GW Pharmaceuticals Down on Disappointing Mid-Stage Data Zacks
04:20PM  Novavax Begins Mid-Stage Study on RSV Vaccine in Elders Zacks
03:30PM  Alnylam Reveals Positive Data from its Pipeline Candidates Zacks
Oct-14-14 11:54AM  J&J Earnings Beat; Olysio Chatter Hits Gilead at Investor's Business Daily
Oct-13-14 04:50PM  Isis Pharmaceuticals Unveils Mid-Stage Data on ISIS-SMNRx Zacks
04:19PM  Celgene's Otezla Encourages in Plaque Psoriasis at EADV Zacks
03:00PM  Targacept's Nine-Year Association with AstraZeneca to End Zacks
Oct-10-14 04:52PM  AstraZeneca's Benralizumab Encourages in Phase II Study Zacks
04:10PM  XOMA Starts Phase I Study on XOMA 358 for Hyperinsulinism Zacks
03:45PM  Momenta Reveals Necuparanib Data for Pancreatic Cancer Zacks
Oct-09-14 05:44PM  What's the Dollar Value of Online Patient Chatter? at BusinessWeek
03:44PM  Amgen Up on Positive Phase III Data on Psoriasis Biosimilar Zacks
03:30PM  Chimerix Falls as Ebola Patient on Brincidofovir Dies in US Zacks
02:26PM  EY Announces leaders from Medivation, MongoDB, Trulia, and zulily inc. recipients of its 2014 Venture Capital Award of Excellence PR Newswire
Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. The company also conducts various trials of enzalutamide in earlier prostate cancer disease states, including the Phase III PREVAIL trial in patients with mCRPC who have not received chemotherapy; and in patients with breast cancer. It has collaboration agreement with Astellas Pharma, Inc. for the development, manufacture, and commercialization of XTANDI. The company is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rhodes Jennifer JGC & Corporate SecretaryMar 02Option Exercise47.482,00094,96014,480Mar 02 09:16 PM
Rhodes Jennifer JGC & Corporate SecretaryMar 02Sale122.002,000244,00012,480Mar 02 09:16 PM
Hung DavidPresident and CEOMar 02Sale120.83100,89112,190,609760,977Mar 02 09:15 PM
FALBERG KATHRYN EDirectorFeb 27Buy117.6725,0002,941,68425,000Mar 02 09:13 PM
Rhodes Jennifer JGC & Corporate SecretaryFeb 26Option Exercise47.482,00094,96014,480Feb 27 04:56 PM
Hung DavidPresident and CEOFeb 26Sale120.1219,1092,295,373861,868Feb 27 04:55 PM
Rhodes Jennifer JGC & Corporate SecretaryFeb 26Sale119.293,089368,50211,391Feb 27 04:56 PM
Machado Clarence PatrickDirectorFeb 10Option Exercise9.3936,000337,86067,500Feb 12 04:21 PM
Machado Clarence PatrickDirectorFeb 10Sale103.8936,0003,739,98431,500Feb 12 04:21 PM
Rhodes Jennifer JGC & Corporate SecretaryFeb 04Sale100.8561061,5198,980Feb 06 07:03 PM
Hung DavidPresident and CEOFeb 04Sale100.483,190320,519861,868Feb 06 07:04 PM
Machado Clarence PatrickDirectorJan 27Option Exercise9.6336,000346,61367,500Jan 29 05:34 PM
Machado Clarence PatrickDirectorJan 27Sale105.3236,0003,791,39231,500Jan 29 05:34 PM
Hung DavidPresident and CEOJan 20Sale108.14100,00010,814,242865,058Jan 22 06:33 PM
Seely LynnChief Medical OfficerDec 19Option Exercise10.1831,340318,94991,194Dec 22 07:42 PM
Rhodes Jennifer JGC & Corporate SecretaryDec 03Sale113.00910102,8309,590Dec 04 04:54 PM
Machado Clarence PatrickDirectorDec 03Sale113.001,580178,54031,500Dec 04 04:53 PM
Hung DavidPresident and CEODec 03Sale113.005,420612,460965,058Dec 04 04:52 PM
Seely LynnChief Medical OfficerOct 22Option Exercise10.595,00052,92564,854Oct 23 06:54 PM
Seely LynnChief Medical OfficerOct 22Sale99.035,000495,14259,854Oct 23 06:54 PM
Seely LynnChief Medical OfficerOct 16Option Exercise10.595,00052,92564,854Oct 17 04:39 PM
Seely LynnChief Medical OfficerOct 16Sale93.975,000469,85059,854Oct 17 04:39 PM
Seely LynnChief Medical OfficerOct 15Option Exercise8.0024,346194,73784,200Oct 17 04:39 PM
Seely LynnChief Medical OfficerOct 15Sale89.1124,3462,169,36359,854Oct 17 04:39 PM
Seely LynnChief Medical OfficerSep 18Option Exercise10.5925,000264,62584,022Sep 18 08:36 PM
Seely LynnChief Medical OfficerSep 18Sale99.8125,0002,495,15859,022Sep 18 08:36 PM
Seely LynnChief Medical OfficerSep 17Option Exercise8.4630,000253,80089,022Sep 18 08:36 PM
Seely LynnChief Medical OfficerSep 17Sale97.3630,0002,920,72759,022Sep 18 08:36 PM
Seely LynnChief Medical OfficerSep 09Option Exercise10.5920,000211,70079,022Sep 11 06:04 PM
Seely LynnChief Medical OfficerSep 09Sale94.6020,0001,892,01659,022Sep 11 06:04 PM
Seely LynnChief Medical OfficerAug 27Option Exercise10.5914,300151,36673,322Aug 28 07:54 PM
Seely LynnChief Medical OfficerAug 27Sale89.6114,3001,281,42359,022Aug 28 07:54 PM
Seely LynnChief Medical OfficerAug 26Option Exercise10.595,70060,33564,722Aug 28 07:54 PM
Seely LynnChief Medical OfficerAug 26Sale88.955,700507,03259,022Aug 28 07:54 PM
Seely LynnChief Medical OfficerAug 13Option Exercise8.3920,000167,82579,022Aug 14 08:00 PM
Seely LynnChief Medical OfficerAug 13Sale83.6220,0001,672,45659,022Aug 14 08:00 PM
Seely LynnChief Medical OfficerAug 12Option Exercise9.3912,500117,31371,522Aug 12 08:49 PM
Seely LynnChief Medical OfficerAug 12Sale84.0112,5001,050,12559,022Aug 12 08:49 PM
Seely LynnChief Medical OfficerAug 08Option Exercise9.3913,000122,00572,022Aug 12 08:49 PM
Seely LynnChief Medical OfficerAug 08Sale82.0613,0001,066,82159,022Aug 12 08:49 PM
Seely LynnChief Medical OfficerJul 22Option Exercise6.747,50050,51366,522Jul 23 06:19 PM
Seely LynnChief Medical OfficerJul 22Sale73.967,500554,71059,022Jul 23 06:19 PM
Seely LynnChief Medical OfficerJul 02Option Exercise9.3912,000112,62071,022Jul 07 07:35 PM
Seely LynnChief Medical OfficerJul 02Sale79.0212,000948,19459,022Jul 07 07:35 PM
Seely LynnChief Medical OfficerJun 18Option Exercise6.747,50050,51366,522Jun 19 04:35 PM
Seely LynnChief Medical OfficerJun 18Sale75.007,500562,53059,022Jun 19 04:35 PM
Seely LynnChief Medical OfficerJun 03Option Exercise6.747,50050,51366,522Jun 19 04:35 PM
Seely LynnChief Medical OfficerJun 03Sale74.507,500558,76059,022Jun 19 04:35 PM